Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance

Nature Immunology

Volumn 5, Issue 5, 2004, Pages 508-515

  Yang, Yiping ^a   Huang, Chang Tai ^b,c   Huang, Xiaopei ^a   Pardoll, Drew M ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; HEMAGGLUTININ; INTERLEUKIN 2 RECEPTOR; LIGAND; TOLL LIKE RECEPTOR; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; GENETIC CODE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS, CD8; IMMUNE TOLERANCE; MEMBRANE GLYCOPROTEINS; MICE; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; VACCINES;

EID: 2442655250     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni1059     Document Type: Article

References (47)

1. Hui, K., Grosveld, F. & Festenstein, H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311, 750-752 (1984).
2. Restifo, N.P. et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265-272 (1993).
3. Torre-Amione, G. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87, 1486-1490 (1990).
4. Ye, X., McCarrick, J., Jewett, L. & Knowles, B.B. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA 91, 3916-3920 (1994).
5. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J. Immunol. 26, 2671-2679 (1996).
6. Staveley-O'Carroll, K. et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95, 1178-1183 (1998).
7. Lee, P.P. et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5, 677-685 (1999).
8. Pardoll, D.M. Cancer vaccines. Nat. Med. 4, 525-531 (1998).
9. Dranoff, G. & Mulligan, R.C. Gene transfer as cancer therapy. Adv. Immunol. 58, 417-454 (1995).
10. Schuler, G. & Steinman, R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186, 1183-1187 (1997).
11. Pardoll, D.M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2, 227-238 (2002).
12. Mayordomo, J.I. et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1, 1297-1302 (1995).
13. Nestle, F.O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332 (1998).
14. Paglia, P., Chiodoni, C., Rodolfo, M. & Colombo, M.P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317-322 (1996).
15. Song, W. et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186, 1247-1256 (1997).
16. Specht, J.M. et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186, 1213-1221 (1997).
17. Dyall, J., Latouche, J.B., Schnell, S. & Sadelain, M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 97, 114-121 (2001).
18. Boczkowski, D., Nair, S.K., Snyder, D. & Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472 (1996).
19. + T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res. 62, 5041-5048 (2002).
20. Smith, G.L., Murphy, B.R. & Moss, B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc. Natl. Acad. Sci. USA 80, 7155-7159 (1983).
21. Panicali, D., Davis, S.W., Weinberg, R.L. & Paoletti, E. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc. Natl. Acad. Sci. USA 80, 5364-5368 (1983).
22. Carroll, M.W. et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15, 387-394 (1997).
23. Paoletti, E., Taylor, J., Meignier, B., Meric, C. & Tartaglia, J. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev. Biol. Stand. 84, 159-163 (1995).
24. Elzey, B.D., Siemens, D.R., Ratliff, T.L. & Lubaroff, D.M. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer 94, 842-849 (2001).
25. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J. Exp. Med. 187, 1555-1564 (1998).
26. + T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J. Immunol. 164, 649-655 (2000).
27. + T cells pass through an effector phase during the process of in vivo tolerance induction. J. Immunol. 170, 3945-3953 (2003).
28. + T cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157, 978-983 (1996).
29. + T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J. Exp. Med. 194, 707-717 (2001).
30. + T cell tolerance to peripherally expressed antigens. J. Immunol. 163, 723-727 (1999).
31. Shortman, K. & Liu, Y.J. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2, 151-161 (2002).
32. Moser, M. Dendritic cells in immunity and tolerance - do they display opposite functions? Immunity 19, 5-8 (2003).
33. Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59, 3128-3133 (1999).
34. + T cell-mediated suppression by dendritic cells. Science 299, 1033-1036 (2003).
35. Ochsenbein, A.F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064 (2001).
36. Lohr, J., Knoechel, B., Jiang, S., Sharpe, A.H. & Abbas, A.K. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat. Immunol. 4, 664-669 (2003).
37. + regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J. Exp. Med. 198, 259-266 (2003).
38. + T cells. Immunity 19, 877-889 (2003).
39. Vaidya, S.A. & Cheng, G. Toll-like receptors and innate antiviral responses. Curr. Opin. Immunol. 15, 402-407 (2003).
40. Kurt-Jones, E.A. et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1, 398-401 (2000).
41. Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732-738 (2001).
42. Yang, Y., Greenough, K. & Wilson, J.M. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 3, 412-420 (1996).
43. Amara, R.R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74 (2001).
44. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96, 2982-2987 (1999).
45. Klein, C., Bueler, H. & Mulligan, R.C. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. 191, 1699-1708 (2000).
46. Miyoshi, H., Blomer, U., Takahashi, M., Gage, F.H. & Verma, I.M. Development of a self-inactivating lentivirus vector. J. Virol. 72, 8150-8157 (1998).
47. Aliberti, J., Hieny, S., Reis e Sousa, C., Serhan, C.N. & Sher, A. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat. Immunol. 3, 76-82 (2002).